CCND1, NOP14 and DNMT3B are involved in miR‐502‐5p–mediated inhibition of cell migration and proliferation in bladder cancer
Yufan Ying(Soochow University), Liping Xie(First Affiliated Hospital Zhejiang University), Xiangyi Zheng(Tianjin University), Xueyou Ma(First Affiliated Hospital Zhejiang University), Jian Wu(Sun Yat-sen University), Liujia He(Zhejiang University), Jiajie Fang(Zhejiang University), Huaqing Yan(Zhejiang University), Haiyun Xie(Zhejiang University), Ben Liu(Yichun University), Xiao Wang(South China Agricultural University), Jiangfeng Li(ShanghaiTech University), Xin Xu(Shanghai University of Sport), Ke Jin(Central South University)
Cited by 68
Related Papers
The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial
|Clinical Cancer Research|2020|576
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276